| Literature DB >> 31673355 |
Siqin Zhang1, Xiucai Zhang1, Qing Wu1, Xiangkuo Zheng2, Guofeng Dong2, Renchi Fang1, Yizhi Zhang1, Jianming Cao2, Tieli Zhou1.
Abstract
Background: Klebsiella pneumoniae-induced pyogenic liver abscess (KP-PLA) has emerged as a life-threatening disease worldwide. However, to date, a limited number of scholars have attempted to systematically elucidate the characteristics of KP-PLA. The aim of the present study was to analyze clinical, microbiological, and molecular epidemiological characteristics of KP-PLA patients in Southeastern China.Entities:
Keywords: Clinical characteristics; Hypervirulent K. pneumoniae; Multidrug resistant; Pyogenic liver abscess; Sequence type; Virulence factors
Mesh:
Substances:
Year: 2019 PMID: 31673355 PMCID: PMC6819602 DOI: 10.1186/s13756-019-0615-2
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Clinical characteristics of K. pneumoniae-induced pyogenic liver abscess
| Clinical characteristic | Value ( |
|---|---|
| Age, years | 63.0 (52.3–70.0) |
| Gender | |
| Male | 100 (61.3) |
| Female | 63 (38.7) |
| Underlying or concomitant conditions | |
| Diabetes mellitus | 81 (49.7) |
| History of intra-abdominal trauma or surgery | 46 (28.2) |
| Hypertension | 41 (25.2) |
| Malignancy | 7 (4.3) |
| Biliary disease | 23 (14.1) |
| Hepatitis and cirrhosis | 8 (4.9) |
| Fatty liver | 14 (8.6) |
| No underlying diseases | 82 (50.3) |
| Admission temperature (°C) | 38.9 (37.8–39.5) |
| Clinical Symptoms | |
| Fever (> 37.5 °C) | 137 (84.0) |
| Chill | 132 (81.0) |
| Abdominal pain | 65 (39.9) |
| Vomit | 24 (14.7) |
| Frail | 25 (15.3) |
| Abdominal distension | 5 (3.1) |
| Invasive procedure | 141 (86.5) |
| Use of hormones and/or immunosuppressants | 52 (31.9) |
| Multiplicity of the abscess | |
| Single | 117 (71.8) |
| Multiple (≥2 abscesses) | 46 (28.2) |
| Site of Single abscess | |
| Right hepatic lobe | 95 (58.3) |
| Left hepatic lobe | 22 (13.5) |
| Laboratory examination | |
| WBC count, × 109/L | 10.8 (7.9–13.4) |
| RBC count, × 1012/L | 3.9 (3.5–4.2) |
| ALT(U/L) | 39.0 (24.0–78.0) |
| AST(U/L) | 37.0 (24.0–68.5) |
| Albumin, g/L | 29.4 ± 5.1 |
| Method of abscess treatment | |
| Simple antibacterial | 30 (18.4) |
| Abscess drainage | 129 (79.1) |
| Surgical removal | 4 (2.5) |
| Prognosis of abscess | |
| Effective | 116 (71.2) |
| Ineffective | 47 (28.8) |
| Metastatic infections | |
| Endophthalmitis | 1 (0.6) |
| Cephalomeningitis | 1 (0.6) |
| Bacterial peritonitis | 1 (0.6) |
| Pneumonia | 1 (0.6) |
| Clinical outcomes | |
| Length of stay in hospital, days | 17.0 (12.0–26.0) |
| Admission to ICU | 16 (9.8) |
| Septic shock | 15 (9.2) |
| Septicemia | 20 (12.3) |
| In-hospital deaths | 1 (0.6) |
Values are presented as median (25th - 75th percentile), mean ± SD or No. (%) of patients
WBC White blood cell, RBC Red blood cell, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ICU Intensive care unit
Microbiological and molecular-epidemiological characteristics of K. pneumoniae strains isolated from KP-PLA patients
| Characteristic | Value ( |
|---|---|
| Hypermucoviscosity | 50 (30.7) |
| Capsular serotypes | |
| K1 | 66 (40.5) |
| K2 | 31 (19.0) |
| K5 | 8 (4.9) |
| K20 | 3 (1.8) |
| non-type | 54 (33.1) |
| Virulence genes | |
| | 139 (85.3) |
| | 155 (95.1) |
| | 40 (24.5) |
| | 116 (71.2) |
| | 112 (68.7) |
| | 120 (73.6) |
| | 74 (45.4) |
| | 156 (95.7) |
| | 163 (100.0) |
| | 147 (90.2) |
| | 144 (88.3) |
| | 145 (89.0) |
| Antimicrobial resistance | |
| Ampicillin | 163 (100.0) |
| Ampicillin/sulbactam | 17 (10.4) |
| Piperacillin/tazobactam | 2 (1.2) |
| Cefazolin | 10 (6.1) |
| Cefotetan | 2 (1.2) |
| Aztreonam | 5 (3.1) |
| Ceftriaxone | 6 (3.7) |
| Ceftazidime | 3 (1.8) |
| Cefepime | 4 (2.5) |
| Cefoperazone/sulbactam | 0 (0.0) |
| Ertapenem | 3 (1.8) |
| Imipenem | 5 (3.1) |
| Ciprofloxacin | 5 (3.1) |
| Levofloxacin | 4 (2.5) |
| Gentamicin | 2 (1.2) |
| Tobramycin | 2 (1.2) |
| Amikacin | 1 (0.6) |
| SMZ-TMP | 6 (3.7) |
| Nitrofurantoin | 34 (20.9) |
| MDR strains | 12 (7.4) |
| CRKP strains | 6 (3.7) |
| Multilocus sequence typing | |
| ST23 | 63 (38.7) |
| ST29 | 10 (6.1) |
| ST65 | 14 (8.6) |
| ST86 | 10 (6.1) |
Values are presented as No. (%) of isolates
MDR Multi-drug resistant, CRKP Carbapenems-resistant K. pneumoniae, SMZ-TMP Sulfamethoxazole and trimethoprim
Fig. 1Comparing the detection rates of virulence genes between K1K2 strains and non-K1K2 strains. *, P < 0.05; **, P < 0.01; ***, P < 0.001
Fig. 2Specific types and quantities of all sequence types among the 163 K. pneumoniae strains
Fig. 3Performing eBURST analysis on molecular epidemiological characteristics of 163 K. pneumoniae isolates. The population snapshot indicates the clonal assignment of the STs presented in this study. Each black dot represents one ST, and blue dots indicate individual founders, while yellow spots denote sub-founders
Comparing clinical characteristics between OHD patients and non-OHD patients from KP-PLA
| Characteristic | OHD patients ( | non-OHD patients ( | |
|---|---|---|---|
| Age, years | 67.0 (62.0-73.0) | 61.0 (51.0-70.0) | 0.053 |
| Gender | 0.451 | ||
| Male | 16 (55.2) | 84 (62.7) | |
| Female | 13 (44.8) | 50 (37.3) | |
| Underlying or concomitant conditions | |||
| Diabetes mellitus | 7 (24.1) | 74 (55.2) | 0.002* |
| History of intra-abdominal trauma or surgery | 26 (89.7) | 20 (14.9) | 0.000* |
| Hypertension | 5 (17.2) | 45 (33.6) | 0.084 |
| Malignancy | 2 (6.9) | 5 (3.7) | 0.797 |
| Admission temperature (°C) | 38.0 (37.3-39.0) | 39.0 (38.0-39.5) | 0.019* |
| Clinical Symptoms | |||
| Fever (>37.5°C) | 20 (69.0) | 117 (87.3) | 0.030* |
| Chill | 23 (79.3) | 109 (81.3) | 0.800 |
| Abdominal pain | 14 (48.3) | 51 (38.1) | 0.308 |
| Vomit | 4 (13.8) | 20 (14.9) | 1.000 |
| Frail | 3 (10.3) | 22 (16.4) | 0.590 |
| Abdominal distension | 2 (6.9) | 3 (2.2) | 0.216 |
| Invasive procedure | 25 (86.2) | 116 (86.6) | 1.000 |
| Use of hormones and/or immunosuppressants | 11 (37.9) | 41 (30.6) | 0.442 |
| Multiplicity of the abscess | 0.409 | ||
| Single | 19 (65.5) | 98 (73.1) | |
| Multiple (≥2 abscesses) | 10 (34.5) | 36 (26.9) | |
| Laboratory examination | |||
| WBC count, ×109/L | 8.9 (5.9-11.6) | 11.1 (8.2-14.0) | 0.014* |
| RBC count, ×1012/L | 3.9 (3.5-4.1) | 3.9 (3.6-4.2) | 0.667 |
| ALT(U/L) | 33.0 (14.0-49.0) | 43.0 (27.0-82.8) | 0.033* |
| AST(U/L) | 35.0 (26.0-50.0) | 37.0 (24.0-70.8) | 0.621 |
| Albumin, g/L | 29.8±5.0 | 29.3±5.1 | 0.609 |
| Method of abscess treatment | |||
| Simple antibacterial | 6 (20.7) | 24 (17.9) | 0.726 |
| Abscess drainage | 20 (69.0) | 109 (81.3) | 0.137 |
| Surgical removal | 3 (10.3) | 1 (0.7) | 0.021* |
| Prognosis of abscess | 0.233 | ||
| Effective | 18 (62.1) | 98 (73.1) | |
| Ineffective | 11 (37.9) | 36 (26.9) | |
| Metastatic infections | 1.000 | ||
| Endophthalmitis | 0 (0.0) | 1 (0.7) | |
| Cephalomeningitis | 0 (0.0) | 1 (0.7) | |
| Bacterial peritonitis | 0 (0.0) | 1 (0.7) | |
| Pneumonia | 0 (0.0) | 1 (0.7) | |
| Clinical outcomes | |||
| Length of stay in hospital, days | 23.0 (15.0-28.0) | 16.0 (12.0-25.0) | 0.045* |
| Admission to ICU | 1 (3.4) | 15 (11.2) | 0.354 |
| Septic shock | 3 (10.3) | 12 (9.0) | 1.000 |
| Septicemia | 5 (17.2) | 15 (11.2) | 0.557 |
| In-hospital deaths | 0 (0.0) | 1 (0.7) | 1.000 |
Values are presented as median (25th - 75th percentile), mean ± SD or No. (%) of patients
WBC white blood cell, RBC red blood cell, ALT alanine aminotransferase, AST aspartate aminotransferase, ICU intensive care unit *P < 0.05
Comparing microbiological and molecular-epidemiological characteristics of K. pneumoniae strains between OHD patients and non-OHD patients
| Characteristic | Kp from OHD patients ( | Kp from non-OHD patients ( | |
|---|---|---|---|
| Hypermucoviscosity | 8 (27.6) | 42 (31.3) | 0.691 |
| Capsular serotypes | |||
| K1 | 11 (37.9) | 55 (41.0) | 0.757 |
| K2 | 5 (17.2) | 26 (19.4) | 0.788 |
| K5 | 1 (3.4) | 7 (5.2) | 1.000 |
| K20 | 1 (3.4) | 2 (1.5) | 0.447 |
| non-type | 11 (37.9) | 43 (32.1) | 0.545 |
| Virulence genes | |||
| | 22 (75.9) | 117 (87.3) | 0.197 |
| | 25 (86.2) | 130 (97.0) | 0.049* |
| | 4 (13.8) | 36 (26.9) | 0.138 |
| | 17 (58.6) | 99 (73.9) | 0.100 |
| | 18 (62.1) | 94 (70.1) | 0.395 |
| | 23 (79.3) | 97 (72.4) | 0.443 |
| | 9 (31.0) | 65 (48.5) | 0.087 |
| | 29 (100.0) | 127 (94.8) | 0.451 |
| | 29 (100.0) | 134 (100.0) | NA |
| | 26 (89.7) | 121 (90.3) | 1.000 |
| | 24 (82.8) | 120 (89.6) | 0.475 |
| | 27 (93.1) | 118 (88.1) | 0.646 |
| Antimicrobial resistance | |||
| Ampicillin | 29 (100.0) | 134 (100.0) | NA |
| Ampicillin/sulbactam | 7 (24.1) | 10 (7.5) | 0.020* |
| Piperacillin/tazobactam | 2 (6.9) | 0 (0.0) | 0.031* |
| Cefazolin | 6 (20.7) | 4 (3.0) | 0.001* |
| Cefotetan | 2 (6.9) | 0 (0.0) | 0.031* |
| Aztreonam | 5 (17.2) | 0 (0.0) | 0.000* |
| Ceftriaxone | 5 (17.2) | 1 (0.7) | 0.000* |
| Ceftazidime | 3 (10.3) | 0 (0.0) | 0.005* |
| Cefepime | 4 (13.8) | 0 (0.0) | 0.001* |
| Cefoperazone/sulbactam | 0 (0.0) | 0 (0.0) | NA |
| Ertapenem | 2 (6.9) | 1 (0.7) | 0.082 |
| Imipenem | 3 (10.3) | 2 (1.5) | 0.040* |
| Ciprofloxacin | 5 (17.2) | 0 (0.0) | 0.000* |
| Levofloxacin | 4 (13.8) | 0 (0.0) | 0.001* |
| Gentamicin | 1 (3.4) | 1 (0.7) | 0.325 |
| Tobramycin | 1 (3.4) | 1 (0.7) | 0.325 |
| Amikacin | 0 (0.0) | 1 (0.7) | 1.000 |
| SMZ-TMP | 4 (13.8) | 2 (1.5) | 0.008* |
| Nitrofurantoin | 13 (44.8) | 21 (15.7) | 0.000* |
| MDR strains | 7 (24.1) | 5 (3.7) | 0.001* |
| CRKP strains | 3 (10.3) | 3 (2.2) | 0.119 |
| Multilocus sequence typing | |||
| ST23 | 6 (20.7) | 57 (42.5) | 0.028* |
| ST29 | 3 (10.3) | 7 (5.2) | 0.538 |
| ST65 | 2 (6.9) | 12 (9.0) | 1.000 |
| ST86 | 2 (6.9) | 8 (6.0) | 1.000 |
Values are presented as No. (%) of isolates
MDR Multi-drug resistant, CRKP Carbapenems-resistant K. pneumoniae, SMZ-TMP sulfamethoxazole and trimethoprim, NA not applicable, *P < 0.05